Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
AMGN | 58.28% | $146.20B | -11.29% | 3.43% |
TMO | 56.55% | $151.18B | -31.55% | 0.40% |
GSK | 53.75% | $78.85B | -13.80% | 4.15% |
NVS | 53.61% | $213.48B | +11.27% | 3.56% |
MTD | 53.58% | $23.61B | -23.21% | 0.00% |
ABBV | 53.36% | $322.44B | +15.34% | 3.50% |
TECH | 52.74% | $7.42B | -41.15% | 0.69% |
RVTY | 52.53% | $10.66B | -19.13% | 0.32% |
DHR | 50.44% | $134.17B | -28.28% | 0.61% |
JNJ | 50.06% | $367.19B | +1.94% | 2.43% |
BMY | 49.31% | $95.71B | +13.22% | 5.21% |
BIIB | 49.25% | $18.51B | -42.08% | 0.00% |
IQV | 48.50% | $23.88B | -39.21% | 0.00% |
NSA | 48.35% | $2.59B | -6.06% | 6.68% |
SNY | 47.36% | $127.94B | +7.16% | 4.27% |
LH | 47.12% | $20.24B | +22.73% | 1.20% |
CUBE | 46.98% | $9.41B | -1.83% | 5.00% |
AVTR | 46.91% | $8.76B | -46.82% | 0.00% |
ES | 46.62% | $23.17B | +9.61% | 4.65% |
DOC | 46.43% | $11.69B | -11.66% | 6.61% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
CANG | 0.03% | $310.90M | +196.15% | 0.00% |
CAMT | -0.06% | $2.96B | -37.63% | 0.00% |
AXON | -0.09% | $56.34B | +158.49% | 0.00% |
HRTG | 0.12% | $710.99M | +180.10% | 0.00% |
UUUU | -0.21% | $975.01M | -31.92% | 0.00% |
BHE | 0.22% | $1.31B | -15.71% | 1.92% |
UEC | -0.22% | $2.21B | -26.70% | 0.00% |
BTBT | -0.26% | $529.84M | +7.14% | 0.00% |
DXCM | 0.30% | $33.26B | -32.46% | 0.00% |
TPB | -0.34% | $1.29B | +121.22% | 0.40% |
INSM | -0.36% | $12.05B | +180.34% | 0.00% |
RLX | 0.36% | $1.83B | +4.15% | 0.50% |
BYRN | 0.38% | $530.64M | +113.01% | 0.00% |
NVDA | -0.41% | $3.24T | +27.97% | 0.03% |
PSN | 0.44% | $7.25B | -12.36% | 0.00% |
NTGR | 0.47% | $859.48M | +130.94% | 0.00% |
AGRO | 0.50% | $949.94M | -3.94% | 3.67% |
FARO | 0.53% | $807.50M | +121.64% | 0.00% |
AQB | 0.54% | $3.27M | -54.75% | 0.00% |
VST | 0.57% | $52.50B | +60.95% | 0.56% |
SeekingAlpha
Teva Pharmaceuticals continues to beat consensus estimates, has once again raised its 2025 financial guidance and secured credit upgrades. Read more on why TEVA stock is a Buy.
Yahoo
Subjects with high-volume disease experienced a 36-month improvement in median OS.
Finnhub
Nona Biosciences announced that its collaborator, Pfizer, will present an abstract detailing the first-in-human Phase 1 clinical study design of MesoC2 , a first-in-class mesothelin -targeting...
Yahoo
We recently published a list of Was Jim Cramer Right About These 12 Stocks? In this article, we are going to take a look at where Pfizer Inc. (NYSE:PFE) stands against other stocks that Jim Cramer discusses. Back in 2024, on May 17, a caller asked about Pfizer Inc. (NYSE:PFE), which had struggled post-COVID. Cramer […]
Yahoo
Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") and Pfizer Inc. (NYSE: PFE) today announced longer-term follow-up results from an open-label extension of the Phase 3 ARCHES (NCT02677896) study, reporting a five-year follow up of overall survival (OS) benefits and a 30% reduction in the risk of death in men with metastatic hormone-sensitive prostate cancer (mHSPC) treated with XTANDI™ (enzalutamide), an androgen receptor pathway inhibitor (ARPI), plus androgen depri
Finnhub
Astellas Pharma Inc: * ASTELLAS AND PFIZER'S XTANDI™ SHOWSLONG-TERMOVERALL SURVIVAL IN METASTATIC HORMONE-SENSITIVE PROSTATE CANCER * PFIZER INC - XTANDI PLUS ADT...
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
FMTO | -11.16% | $42.10M | -99.95% | 0.00% |
STG | -8.32% | $26.51M | -45.13% | 0.00% |
XGN | -8.09% | $131.79M | +201.50% | 0.00% |
GALT | -7.72% | $81.01M | -58.03% | 0.00% |
LITB | -6.29% | $25.74M | -66.23% | 0.00% |
VSA | -6.15% | $6.72M | -45.11% | 0.00% |
QXO | -6.03% | $8.79B | -83.17% | 0.00% |
VSTA | -5.34% | $320.81M | +14.29% | 0.00% |
CNK | -5.28% | $3.73B | +82.76% | 0.25% |
STRL | -5.22% | $5.54B | +45.33% | 0.00% |
CYCN | -4.39% | $10.43M | +9.80% | 0.00% |
QNTM | -3.69% | $28.10M | -47.59% | 0.00% |
ALAR | -3.66% | $54.42M | -76.42% | 0.00% |
IESC | -3.58% | $4.80B | +52.44% | 0.00% |
CARV | -3.17% | $7.72M | -14.69% | 0.00% |
POWL | -2.78% | $2.09B | -6.20% | 0.63% |
TLN | -2.76% | $10.86B | +112.40% | 0.00% |
IAG | -2.75% | $3.78B | +69.77% | 0.00% |
AIFU | -2.24% | $191.32M | +5.63% | 0.00% |
OXBR | -2.19% | $12.95M | -21.97% | 0.00% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
PPH | 68.27% | $604.48M | 0.36% |
BBH | 65.53% | $340.78M | 0.35% |
IXJ | 64.38% | $3.87B | 0.41% |
FHLC | 63.76% | $2.46B | 0.084% |
VHT | 63.70% | $15.32B | 0.09% |
XLV | 63.63% | $35.08B | 0.09% |
IYH | 63.59% | $2.81B | 0.39% |
RSPH | 63.02% | $768.87M | 0.4% |
FDL | 62.81% | $5.45B | 0.45% |
IHE | 62.50% | $563.21M | 0.39% |
IBB | 62.35% | $5.41B | 0.45% |
SPHD | 60.52% | $3.25B | 0.3% |
FBT | 60.51% | $1.05B | 0.56% |
SCHD | 59.15% | $68.80B | 0.06% |
FXH | 57.92% | $927.09M | 0.62% |
PBE | 57.61% | $224.25M | 0.58% |
SPYD | 56.83% | $6.90B | 0.07% |
SDOG | 56.61% | $1.19B | 0.36% |
FVD | 56.10% | $9.16B | 0.6% |
HDV | 56.07% | $11.08B | 0.08% |
Current Value
$23.041 Year Return
Current Value
$23.041 Year Return
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
VIXY | -30.63% | $126.83M | 0.85% |
TAIL | -24.40% | $118.71M | 0.59% |
TPMN | -15.15% | $30.83M | 0.65% |
IVOL | -13.97% | $355.73M | 1.02% |
CLIP | -13.79% | $1.51B | 0.07% |
BTAL | -8.49% | $360.65M | 1.43% |
KCCA | -6.10% | $95.01M | 0.87% |
FTSD | -5.22% | $212.66M | 0.25% |
CANE | -4.39% | $10.30M | 0.29% |
SHYM | -4.19% | $323.08M | 0.35% |
GBIL | -3.90% | $6.06B | 0.12% |
FMF | -3.11% | $151.32M | 0.95% |
UUP | -2.39% | $277.56M | 0.77% |
BIL | -2.03% | $45.04B | 0.1356% |
XBIL | -2.00% | $778.49M | 0.15% |
FXY | -1.92% | $857.57M | 0.4% |
CORN | -1.66% | $50.30M | 0.2% |
USDU | -1.52% | $169.80M | 0.5% |
TBLL | -1.45% | $2.31B | 0.08% |
UGA | -1.27% | $72.78M | 0.97% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
TBIL | -0.11% | $5.81B | 0.15% |
XHLF | 0.12% | $1.46B | 0.03% |
JMST | -0.18% | $3.71B | 0.18% |
SGOV | 0.47% | $46.65B | 0.09% |
XONE | -0.59% | $610.73M | 0.03% |
ULST | -0.60% | $638.58M | 0.2% |
SOYB | 0.65% | $25.14M | 0.22% |
CTA | -0.81% | $1.08B | 0.76% |
WEAT | -0.98% | $121.36M | 0.28% |
DBE | 1.05% | $46.64M | 0.77% |
USL | 1.05% | $40.94M | 0.85% |
OILK | 1.09% | $61.94M | 0.69% |
FXE | 1.24% | $520.10M | 0.4% |
UGA | -1.27% | $72.78M | 0.97% |
BNO | 1.44% | $87.37M | 1% |
TBLL | -1.45% | $2.31B | 0.08% |
AGZD | 1.49% | $109.45M | 0.23% |
USDU | -1.52% | $169.80M | 0.5% |
TFLO | 1.65% | $7.03B | 0.15% |
CORN | -1.66% | $50.30M | 0.2% |
Double maintains 12 strategies that include PFE - Pfizer Inc.